BG102014A - Carbapenem esters - Google Patents

Carbapenem esters

Info

Publication number
BG102014A
BG102014A BG102014A BG10201497A BG102014A BG 102014 A BG102014 A BG 102014A BG 102014 A BG102014 A BG 102014A BG 10201497 A BG10201497 A BG 10201497A BG 102014 A BG102014 A BG 102014A
Authority
BG
Bulgaria
Prior art keywords
carbapenem
esters
carbapenem esters
methyl
benzoyloxyemethyl
Prior art date
Application number
BG102014A
Other languages
Bulgarian (bg)
English (en)
Inventor
George Burton
Stephen MOSS
Alfred EGLINGTON
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9508956.1A external-priority patent/GB9508956D0/en
Priority claimed from GBGB9508955.3A external-priority patent/GB9508955D0/en
Priority claimed from GBGB9508957.9A external-priority patent/GB9508957D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG102014A publication Critical patent/BG102014A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02Preparation
    • C07D477/06Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C07D477/08Modification of a carboxyl group directly attached in position 2, e.g. esterification
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG102014A 1995-05-03 1997-11-03 Carbapenem esters BG102014A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9508956.1A GB9508956D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9508955.3A GB9508955D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9508957.9A GB9508957D0 (en) 1995-05-03 1995-05-03 Novel compounds
PCT/EP1996/001880 WO1996034868A1 (en) 1995-05-03 1996-05-02 Esters of carbapenems

Publications (1)

Publication Number Publication Date
BG102014A true BG102014A (en) 1998-11-30

Family

ID=27267696

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102014A BG102014A (en) 1995-05-03 1997-11-03 Carbapenem esters

Country Status (22)

Country Link
EP (1) EP0823910A1 (xx)
JP (1) JPH11504910A (xx)
KR (1) KR19990008355A (xx)
CN (1) CN1185783A (xx)
AR (1) AR005416A1 (xx)
AU (1) AU5813996A (xx)
BG (1) BG102014A (xx)
BR (1) BR9608313A (xx)
CA (1) CA2217990A1 (xx)
CZ (1) CZ347597A3 (xx)
EA (1) EA199700293A1 (xx)
HU (1) HUP9801066A3 (xx)
IL (1) IL118092A0 (xx)
MA (1) MA23853A1 (xx)
MX (1) MX9708421A (xx)
NO (1) NO974994D0 (xx)
OA (1) OA10632A (xx)
PE (1) PE50697A1 (xx)
PL (1) PL323141A1 (xx)
SK (1) SK146497A3 (xx)
TR (1) TR199701286T1 (xx)
WO (1) WO1996034868A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2013157583A1 (ja) * 2012-04-18 2013-10-24 大日本住友製薬株式会社 新規カルバペネム化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593524A (en) * 1976-11-19 1981-07-15 Merck & Co Inc 1-carba-2-penem-3-carboxylic acids
CA1212105A (en) * 1980-04-30 1986-09-30 Shoji Ikeda Ampicillin esters and production thereof
AU7467194A (en) * 1993-08-18 1995-03-14 Sankyo Company Limited Crystalline carbapenem derivatives
KR960705827A (ko) * 1993-10-29 1996-11-08 데이비드 로버츠 2-(피라졸-3-일)카르바페넴 유도체(2-(pyrazol-3-yl)carbapenem derivatives)

Also Published As

Publication number Publication date
NO974994L (no) 1997-10-30
CN1185783A (zh) 1998-06-24
PL323141A1 (en) 1998-03-16
SK146497A3 (en) 1998-05-06
MA23853A1 (fr) 1996-12-31
HUP9801066A2 (hu) 1998-08-28
BR9608313A (pt) 1999-01-26
OA10632A (en) 2002-09-16
WO1996034868A1 (en) 1996-11-07
EA199700293A1 (ru) 1998-06-25
CA2217990A1 (en) 1996-11-07
MX9708421A (es) 1998-02-28
CZ347597A3 (cs) 1998-08-12
AR005416A1 (es) 1999-06-23
EP0823910A1 (en) 1998-02-18
IL118092A0 (en) 1996-09-12
HUP9801066A3 (en) 1999-01-28
AU5813996A (en) 1996-11-21
TR199701286T1 (xx) 1998-02-21
NO974994D0 (no) 1997-10-30
JPH11504910A (ja) 1999-05-11
KR19990008355A (ko) 1999-01-25
PE50697A1 (es) 1997-12-18

Similar Documents

Publication Publication Date Title
AU5370096A (en) Method of treating or preventing non-viral microbial infection
AU6529796A (en) Biological agent compositions
AU5362696A (en) Compounds and methods for the dectection of t. cruzi infection
AU2663097A (en) Compounds and methods for the selective treatment of cancer and bacterial infections
AU5750796A (en) System for the treatment of insomnia
AU5860396A (en) Substituted oxazoles for the treatment of inflammation
AU685029B2 (en) Method of strengthening antibacterial action of antibiotics
BG104117A (en) Universally applicable blood plasma
AU5254696A (en) Reduced toxicity compositions and methods for treating hiv infections
FI960193A0 (fi) Menetelmä mikro-organismien deaktivoimiseksi
AU3328693A (en) Treatment of fungal infections
MX9708611A (es) Compuestos de dialquiltiacumicina.
IL122942A0 (en) Esters of 1-beta-d-arabinofuranosylcytosine and pharmaceutical compositions containing them
AU3279093A (en) Method for decreasing the allergenicity of psyllium seed husk by enzyme treatment
AU5758594A (en) Treatment of viral infections
AU6231594A (en) Biologically active compounds isolated from aerobic fermentation of (trichoderma viride)
BG102014A (en) Carbapenem esters
AU1684897A (en) Composition for organ cryopreservation and treatment of viral and bacterial infections
AU1192797A (en) Oxidase, microorganisms producing the same and use of the same
NO973366L (no) Fremgangsmåte for behandling av multippel sklerose
NZ332453A (en) (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-[(2S,4S)-2-[(3R)-3-methylaminomethylpyrrolidin-1-ylcarbonyl]pyrrolidin-4-ylthio]-1-carbapen-2-em-3-carboxylic acid for the prevention or treatment of bacterial infections
FR2689518B1 (fr) Microorganismes, procédé de préparation et utilisation.
AU6352994A (en) Flocculated microbial inoculants for delivery of agriculturally beneficial microorganisms
WO1996026728A3 (en) Use of moxonidine for the treatment of atherosclerosis
AU1593792A (en) Treatment of mastitis